Stockreport

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026 Up to $440.0 million in milestone payments elig [Read more]